LARIO THERAPEUTICS

FIGHTING
NEUROLOGICAL
DISORDERS WITH
PRECISION
MEDICINE

Precision Neuroscience
Today

Lario Therapeutics are developing first-in-class precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson’s disease. Our rapidly advancing pipeline begins with genetically validated targets and promises broad therapeutic potential, with a chance to slow the progression of these devastating early childhood syndromes and adult neurological disorders.

OUR SCIENCE

LATEST NEWS

Breakthrough personalized medicine approaches for neurological disorders

OUR COMPANY

Lario Therapeutics was founded in 2021 as a spin-out from Epidarex Exeed, the therapeutic discovery engine of Epidarex Capital, with seed investment from Epidarex Capital and Axxam (which transferred to Golgi Neurosciences)

Targeting severe developmental & epileptic encephalopathies and neurodegenerative disorders

OUR PIPELINE

First-in-class precision medicines for disease modifying treatments in severe neurological disorders including epileptic conditions and Parkinson’s disease. Rapidly advancing a pipeline of genetically validated programs towards the clinic.